Company Analysis Acrivon Therapeutics, Inc.
1. Summary
Advantages
- Price (1.13 $) is less than fair price (5.88 $)
Disadvantages
- Dividends (0%) are below the sector average (0.542%).
- The stock's return over the last year (-87.63%) is lower than the sector average (-31.73%).
- Current debt level 1.85% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-54.07%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Acrivon Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -5.2% | -20.3% | 7% |
| 90 days | -79.7% | -34.1% | -3.8% |
| 1 year | -87.6% | -31.7% | 14.7% |
ACRV vs Sector: Acrivon Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -55.9% over the past year.
ACRV vs Market: Acrivon Therapeutics, Inc. has significantly underperformed the market by -102.36% over the past year.
Slightly volatile price: ACRV is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: ACRV with weekly volatility of -1.69% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (1.13 $) is lower than the fair price (5.88 $).
Price significantly below the fair price: The current price (1.13 $) is 420.4% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (63.25).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (90.33).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (11.51) is lower than that of the sector as a whole (18.83).
P/BV vs Market: The company's P/BV (11.51) is higher than that of the market as a whole (9.51).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (32.67).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (10.25).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-22.4) is lower than that of the sector as a whole (274.42).
EV/Ebitda vs Market: The company's EV/Ebitda (-22.4) is lower than that of the market as a whole (51.38).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 283.98% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (283.98%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-54.07%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-54.07%) is lower than that of the market as a whole (9.57%).
5.5. ROA
ROA vs Sector: The company's ROA (-48.11%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-48.11%) is lower than that of the market as a whole (6.63%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.542%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
